World Library  
Flag as Inappropriate
Email this Article

Spectrum Pharmaceuticals

Article Id: WHEBN0023149582
Reproduction Date:

Title: Spectrum Pharmaceuticals  
Author: World Heritage Encyclopedia
Language: English
Subject: Ortataxel, Satraplatin, Aderis Pharmaceuticals, Zonite Products Corporation, Qualitest
Publisher: World Heritage Encyclopedia

Spectrum Pharmaceuticals

Spectrum Pharmaceuticals
Type Public
Industry Pharmaceuticals
Headquarters Henderson, Nevada
Key people R. Shrotriya, Chief Executive Officer

Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.


Spectrum's drugs are for treatments in oncology and urology.

Approved drugs

In the US, Spectrum markets Fusilev, Folotyn, Marqibo, and Zevalin.

Fusilev (Levoleucovorin) for injection is a drug that was approved by the U.S. Food and Drug Administration in 2008 for the US; the drug had been on the market in a number of European countries.

Folotyn (pralatrexate) is marketed for relapsed or refractory Peripheral T-cell lymphoma.

Zevalin (Ibritumomab Tiuxetan), as part of the Zevalin therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL. It has been approved by the FDA in 2002.

Marqibo (Vincristine sulfate liposomes injection) is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo's approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. It had been approved by the FDA in 2012. [1]

In development

A number of drugs are currently investigated in clinical trials.[2]

EOquin (Apaziquone) is a synthetic bio-reductive prodrug intended for the treatment of non-invasive bladder cancer that is currently in Phase 3 studies. Allergan has invested money in 2008 to help develop this medication further and bring it to the market.[3] In Phase 2 studies are Ozarelix, for the treatment of prostate cancer and benign prostatic hypertrophy, Ortataxel, for the treatment of taxane-refractory tumors, and Satraplatin,for non-small cell lung cancer (NSCLC).

Other medications are in development or Phase 1 studies.


  1. ^®-vinCRIStine-sulfate-LIPOSOME
  2. ^ Clinical trials
  3. ^ Marcial G. "Cancer drugs from Spectrum".  

External links

  • Official site
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.

Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.